-
-
According to new data from the Centers for Disease Control and Prevention's (CDC's) 2013 National Immunization Survey Teen, the number of girls and boys ages 13-17 years receiving human papillomavirus (HPV) vaccine remains unacceptably low, despite a slight increase in vaccination coverage since 2012.
-
Availability of emergency contraception (EC) has broadened since the FDA ruled that generic EC could be sold on store shelves and would no longer require proof of age.
-
Data presented at the AIDS 2014 international conference indicates that oral HIV pre-exposure prophylaxis (PrEP) provides a high degree of protection against HIV infection, even for individuals who miss some daily doses.
-
Science is looking at a wireless microchip implant, with remote drug delivery control, that is designed to last up to 16 years.
-
Presentations at the AIDS 2014 conference offer differing outlooks on increased risk of HIV in women using contraceptive injections.
-
Long-acting reversible contraception (LARC) — the copper T and levonorgestrel intrauterine devices (IUDs) and the birth control implant — are the most effective reversible methods available to prevent unintended pregnancy. They last for several years and are easy to use. Clinicians can draw lessons from the Contraceptive CHOICE project in St. Louis on how to make their clinics "LARC First.
-
Good news for patients at your clinic: The second-generation FC2 Female Condom is available for purchase in the United States, which gives American women a nonlatex, female-controlled option in disease protection.
-
Women in the United States now account for more than one-quarter of all new HIV/AIDS diagnoses.
-
Update your clinical practice; make your plans now for the following 2010 conferences:
